Natixis Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$75.5M Sell
195,156
-16,008
-8% -$5.94M 0.08% 211
2026
Q1
$61.8M Sell
211,164
-55,898
-21% -$18.4M 0.09% 228
2025
Q4
$93.6M Buy
267,062
+22,267
+9% +$7.52M 0.13% 161
2025
Q3
$79.1M Buy
244,795
+54,738
+29% +$17M 0.12% 184
2025
Q2
$73.9M Buy
190,057
+24,513
+15% +$9.86M 0.12% 188
2025
Q1
$72M Buy
165,544
+42,114
+34% +$16.9M 0.13% 171
2024
Q4
$45.5M Sell
123,430
-68,666
-36% -$28.7M 0.09% 238
2024
Q3
$99.9M Buy
192,096
+14,502
+8% +$7.75M 0.19% 114
2024
Q2
$96.2M Buy
177,594
+5,662
+3% +$2.99M 0.21% 106
2024
Q1
$89.2M Buy
171,932
+11,209
+7% +$5.57M 0.21% 110
2023
Q4
$75.8M Buy
160,723
+17,799
+12% +$8.23M 0.2% 122
2023
Q3
$62.2M Buy
142,924
+11,067
+8% +$5.02M 0.19% 120
2023
Q2
$58.6M Sell
131,857
-31,490
-19% -$14.5M 0.18% 135
2023
Q1
$75.1M Sell
163,347
-3,897
-2% -$1.85M 0.26% 98
2022
Q4
$85.8M Sell
167,244
-18,953
-10% -$9.62M 0.32% 82
2022
Q3
$84.6M Buy
186,197
+9,141
+5% +$4.37M 0.36% 62
2022
Q2
$85.4M Buy
177,056
+1,571
+0.9% +$777K 0.38% 63
2022
Q1
$86.2M Buy
175,485
+9,412
+6% +$4.3M 0.33% 68
2021
Q4
$77M Buy
166,073
+9,077
+6% +$3.82M 0.29% 74
2021
Q3
$58.5M Sell
156,996
-731
-0.5% -$278K 0.24% 90
2021
Q2
$60.2M Buy
157,727
+5,918
+4% +$2.26M 0.28% 75
2021
Q1
$54.5M Buy
151,809
+4,657
+3% +$1.5M 0.28% 74
2020
Q4
$47.2M Buy
147,152
+6,977
+5% +$2.14M 0.27% 78
2020
Q3
$37.6M Buy
140,175
+592
+0.4% +$159K 0.24% 95
2020
Q2
$36.7M Buy
139,583
+12,878
+10% +$3.44M 0.24% 91
2020
Q1
$28.8M Buy
126,705
+14,797
+13% +$4.03M 0.23% 95
2019
Q4
$33.8M Buy
111,908
+14,752
+15% +$4.06M 0.24% 88
2019
Q3
$23.3M Sell
97,156
-18,481
-16% -$5.06M 0.19% 132
2019
Q2
$32.6M Buy
115,637
+17,439
+18% +$4.76M 0.27% 84
2019
Q1
$28.2M Sell
98,198
-5,675
-5% -$1.64M 0.25% 90
2018
Q4
$27.3M Buy
103,873
+2,670
+3% +$734K 0.27% 79
2018
Q3
$27.7M Sell
101,203
-14,852
-13% -$3.86M 0.24% 84
2018
Q2
$27.6M Buy
116,055
+2,479
+2% +$574K 0.26% 81
2018
Q1
$25M Buy
113,576
+1,570
+1% +$369K 0.25% 81
2017
Q4
$25.2M Sell
112,006
-2,264
-2% -$482K 0.26% 73
2017
Q3
$21.7M Sell
114,270
-1,289
-1% -$245K 0.23% 89
2017
Q2
$21.7M Sell
115,559
-46,917
-29% -$8.43M 0.24% 84
2017
Q1
$26.9M Sell
162,476
-6,567
-4% -$1.04M 0.3% 61
2016
Q4
$24.3M Buy
169,043
+1,409
+0.8% +$189K 0.29% 70
2016
Q3
$21M Sell
167,634
-1,695
-1% -$219K 0.27% 77
2016
Q2
$22.2M Buy
169,329
+12,818
+8% +$1.75M 0.31% 70
2016
Q1
$21.8M Buy
156,511
+101,608
+185% +$13.6M 0.33% 62
2015
Q4
$7.66M Buy
54,903
+3,638
+7% +$501K 0.13% 206
2015
Q3
$7.18M Sell
51,265
-5,358
-9% -$805K 0.12% 214
2015
Q2
$9.29M Sell
56,623
-2,377
-4% -$380K 0.16% 170
2015
Q1
$9.11M Buy
59,000
+20,062
+52% +$2.86M 0.16% 155
2014
Q4
$4.89M Sell
38,938
-3,117
-7% -$385K 0.09% 337
2014
Q3
$5.03M Buy
42,055
+10,186
+32% +$1.17M 0.1% 311
2014
Q2
$3.43M Buy
31,869
+4,650
+17% +$479K 0.05% 547
2014
Q1
$2.71M Sell
27,219
-707
-3% -$63.9K 0.04% 564
2013
Q4
$2.58M Buy
27,926
+2,631
+10% +$234K 0.04% 554
2013
Q3
$2.12M Sell
25,295
-6,163
-20% -$528K 0.04% 563
2013
Q2
$2.57M Buy
+31,458
New +$2.35M 0.05% 498

Other funds holding ELV

Natixis Advisors's ELV Position: Q2 2026 in Review

Natixis Advisors reduced its Elevance Health (ELV) stake by 7.6% in Q2 2026, selling an estimated $5.94M and leaving 195,156 shares worth $75.5M. The position accounts for 0.08% of the portfolio, ranked #211.

Natixis Advisors first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $99.9M in Q3 2024. 1,600 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Natixis Advisors held 195,156 shares of Elevance Health worth $75.5M as of Q2 2026.
  • Natixis Advisors sold 16,008 Elevance Health shares in Q2 2026, an estimated $5.94M.
  • Elevance Health made up 0.08% of Natixis Advisors's portfolio in Q2 2026, its #211 holding.
  • Natixis Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • Natixis Advisors's Elevance Health position peaked at $99.9M in Q3 2024.
  • 1,600 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.